B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes. Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies. Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management. In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
This program is also available as a podcast. You may download it here: https://anchor.fm/LargeB-CellLymphoma
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
This activity was developed for regional and national audiences of hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with large B-cell lymphomas (LBCL).
This activity is being supported by an educational grant from Bristol Myers Squibb.
Jeremy S. Abramson, MD, MMSc
Director, Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School